tumor

Dying Tumor Cells Suppress Anti-Cancer Immune Response

IRP Study Points to Strategies to Stop Disease From Spreading

T cells (red) attacking cancer cell (white)

Ancient Greek myth describes how the hero Hercules battled the many-headed hydra, which regrew two heads every time Hercules cut one off. This frustrating fight against a seemingly invulnerable opponent would be an apt metaphor for treating cancer, in which tumor cells sometimes die in a particular way that actually helps their brethren multiply and spread to other parts of the body. In a study of that phenomenon using a mouse model of breast cancer, IRP researchers discovered that it occurs because that form of cell death suppresses the immune system’s response to the cancer, a finding that points to several potential ways to improve cancer therapy.

Creating Cutting-Edge Cancer Vaccines

IRP Research Identifies a Tantalizing Target for Cancer Immunotherapy

person getting vaccine injection

February 4 is World Cancer Day, a time to mark international efforts to prevent, detect, and treat cancer. Immunotherapy, one of the most significant advances in treating cancer, was pioneered here at NIH more than 30 years ago. Today, IRP senior investigator Claudia M. Palena, Ph.D., is pushing cancer immunotherapy forward with the discovery of a novel target for cancer vaccines.

African Ancestry May Influence Immune Response to Prostate Cancer

IRP Study Could Help Explain Racial Disparities in Disease Outcomes

black man getting blood drawn by nurses

Even as advances in therapy are extending the lives of many cancer patients, there are still stark differences in how likely patients of different races and ethnicities are to die from the disease. A recent IRP study suggests that a weaker immune response against cancer could explain the worse clinical outcomes for Black men with prostate cancer, pointing to potential strategies that could help close this gap.

Inflammation Contributes to Cancer-Related Fatigue

Mouse Study Suggests Approach to Combat Patients’ Debilitating Tiredness

exhausted person in bed

The human body is like any delicate ecosystem — disrupting just one part of it can have unexpected, widespread repercussions. Cancer patients know this well, not just because a tumor confined to one organ can cause a range of symptoms, but also because radiation treatment aimed specifically at the tumor sometimes leaves patients feeling utterly exhausted. New IRP research suggests that an inflammatory response to targeted radiation therapy is responsible for this common side effect of the treatment.

A Ray of Hope for a Rare and Deadly Skin Cancer

IRP Research Leads to First FDA-Approved Therapy for Merkel Cell Carcinoma

Dr. James Gulley talking with a patient

May is Skin Cancer Awareness Month. Skin cancers are the most common cancer in the U.S., affecting as many as five million people every year. Yet the rarest of these cancers is also one of the deadliest. Merkel cell carcinoma affects about 3,000 Americans each year, and until recently a lack of effective treatments meant only half of patients survived five years or longer after diagnosis. The median survival was nine months.

This bleak outlook changed radically in 2017 with the US Food and Drug Administration (FDA) approval of a new immunotherapy drug called avelumab. Developed through a collaboration between IRP researchers and the pharmaceutical company EMD Serono, Inc., and marketed as Bavencio, avelumab was the first treatment approved specifically for Merkel cell carcinoma.

IRP’s John T. Schiller Elected to National Academy of Sciences

NIH Scientist’s Decoy Virus Revolutionizes Cervical Cancer Prevention

Dr. John T. Schiller

The National Academy of Sciences (NAS), established in 1863, is comprised of the United States’ most distinguished scientific scholars, including nearly 500 Nobel Prize winners. Members of the NAS are elected by their peers and entrusted with the responsibility of providing independent, objective advice on national matters related to science and technology in an effort to advance innovations in the United States.

IRP senior investigator John T. Schiller, Ph.D., was elected to the NAS in 2020 in recognition of a career that has produced numerous discoveries about human papillomaviruses (HPV), sexually transmitted infections that cause genital warts and are responsible for most cases of cervical cancer. His decades-long partnership with fellow IRP senior investigator Douglas R. Lowy, M.D., who was elected to the NAS in 2009, has yielded a deeper understanding of how HPV infects and damages cells and led to the creation of the first vaccines to prevent HPV infection.

Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer

Study Also Reveals Immunotherapy’s Target on Cancer Cells

antibodies

In the 1995 film The Usual Suspects, Kevin Spacey’s con man character famously remarks, “The greatest trick the Devil ever pulled was convincing the world he didn't exist.” The same could be said of cancer, which somehow persuades the body it is not a threat. Cutting-edge treatments called immunotherapies remove this façade and encourage the immune system to attack cancer cells. New IRP research in mice has demonstrated the promise of a new immunotherapy for treating ovarian cancer and identified a marker on cancer cells that could help clinicians identify patients who are most likely to benefit from the therapy.

Gene Editing Reveals Potential Cancer Treatment Target

Scientists Parse Wide-Ranging Effects of Endometrial Cancer Mutation

a piece of DNA being removed from a DNA molecule

The so-called ‘butterfly effect’ supposes that a butterfly flapping its wings in Brazil can cause a tornado in Texas. While the jury is still out on insect-induced natural disasters, it is clear that a single genetic mutation can have wide-ranging and unexpected consequences throughout a cell. By examining the ripple effects caused by changes in a particular gene, IRP researchers have identified a potential treatment target for a particularly deadly variety of cancer.

A Country-Spanning Cancer Collaboration

Scientific Team-Up Identifies Source of Tumor Drug Resistance

acute myeloid leukemia cells

It’s an unfortunate reality that nearly everyone knows somebody whose life has been affected by cancer. However, a discovery by two researchers who met by chance years ago might one day help more cancer patients overcome their disease. Two scientific teams led by the IRP’s Craig Thomas, Ph.D., a group leader at the NIH’s National Center for Advancing Translational Sciences (NCATS), and Daniel Starczynowski, Ph.D., of Cincinnati Children’s Hospital Medical Center, recently published a study describing a possible breakthrough in the fight against acute myeloid leukemia (AML), a form of cancer responsible for nearly 11,000 deaths per year in the United States.

New Treatment Creates Unwelcome Environment for Breast Cancer

Modifying Tumor’s Surroundings Stymies Cancer’s Expansion

breast cancer tumor

If you ever tried planting an apple tree in the desert or growing avocados in New England, you would quickly figure out that such plants need a particular environment in order to thrive. Cancerous tumors are no different, and IRP researchers recently found strong evidence that a molecule naturally produced in the body can suppress the growth and spread of a particularly lethal form of breast cancer via both direct effects on the cancer and by altering its surroundings.